Does parenteral recombinant human neuregulin-1 improve haemodynamic responses in patients with stable chronic heart failure?
Parenteral rhNRG-1 produces favorable hemodynamic effects in stable chronic heart failure, warranting further investigation in randomized trials.
rhNRG-1 appears to produce favourable acute and chronic haemodynamic effects in patients with stable CHF on optimal medical therapy. Randomized controlled trials of rhNRG-1 in cardiac disease are thus warranted. Clinical Trial Registration Information The trial was registered with the Australian New Zealand Clinical Trials Registry, anzctr.org.au Identifier: ACTRN12607000330448.
Jabbour et al. (2010) studied this question.